

## QIBA FDG-PET Biomarker Committee (BC) Call

07 July 2017 at 9 AM CT

Call Summary

### In attendance:

<i>Rathan Subramaniam, MD, PhD, MPH (Co-Chair)</i>	Adriaan Lammertsma, PhD	Mitsuaki Tatsumi, MD	<b>RSNA</b> Joe Koudelik
<i>Scott Wollenweber, PhD (Co-Chair)</i>	Nancy Obuchowski, PhD	Pierre Tervé, MS	Susan Weinmann
Edward Jackson, PhD	Amy Perkins, PhD	Jeffrey Yap, PhD	
Jeff Kolthammer, PhD	Eric Perlman, MD		

**Moderator:** Dr. Wollenweber

### Highlights from the Society of Nuclear Medicine and Molecular Imaging Annual Meeting (June 10-14, 2017)

- Dr. Turkington gave a presentation on preliminary results for reproducibility using simple phantoms to reveal variability
  - These results may be used to determine QIBA performance criteria
- Dr. Lodge discussed phantom advanced reconstruction techniques and their impact on quantitative measurements
- $SUV^{peak}$  to further be included in Claim Confirmed Profile analysis

### Moving the FDG-PET/CT Profile to [Claim Confirmed](#)

- Funding being investigated based on simultaneous completion of Stage 4: Claim-Confirmed & Stage 5: Clinically-Confirmed
- FDG-PET BC decision on whether to combine Stages 4 & 5 will inform other logistics
- It is acceptable to combine stages 4 & 5 as long as all requirements are met for Stage 5; BC consensus needed
- Requirements for stages 4 & 5 regarding number/type of sites, patient sample size, etc. to be defined with Dr. Obuchowski's assistance; the FDG-PET BC encouraged to continue progress on writing protocol in the meantime
- Funding and operational support to be determined

### FDG-PET Checklist

- The BC hopes to partner with ECOG-ACRIN in order to test performance of the claim with functional validation
- At present, no decision has been made; agreements with ECOG-ACRIN would need to be reviewed and confirmed
- A draft proposal will be prepared for discussion
- Confirmation from *Radiology* editor, Dr. Kressel that manuscript will be considered for publication in *Radiology*
  - Manuscript to be submitted to *Radiology* before August. 1; if submitted after this date, confirmation would need to be obtained from new editor, Dr. Bluemke
- Dr. Obuchowski has calculated site/patient numbers for small 4-site study (e.g. stage 4); details for a larger, more generalized study (e.g. Stage 5) to be calculated for comparison
- Subramaniam to write introduction and rationale while other issues regarding protocol are under discussion

- Suggestion to leverage relationships with more imaging iCROs
  - NBDA opportunity to be leveraged to get more iCRO involvement; comparing the current FDG-PET protocols used by both suggested to identify performance gaps
  - NBDA efforts incorporated both quantitative & qualitative FDG-PET, as qualitative aspect was required with lymphoma as topic
  - QIBA FDG-PET checklist focused mainly on quantitative, as it concerns solid tumors
  - Proposal to obtain feedback from imaging iCROs on QIBA's quantitative work, as there is an interest in determining the differences between the two checklists in regard to technical requirements

**Action items (ongoing)**

- Dr. Kinahan to follow up with potential authors regarding authorship for the proposed *Radiology* article
- Dr. Wollenweber to follow up with Dr. Kinahan re: status of manuscript
- Dr. Subramaniam to enquire with the *AJR* editor re: a possible back-up or parallel manuscript publication

**Nuclear Medicine WebEx Schedule:**

<b>7/14</b>	PET Amyloid BC	<b>7/28</b>	NM Leadership (TBD)
<b>7/18</b>	SPECT TF (TBD)	<b>8/1</b>	SPECT TF (TBD)
<b>7/21</b>	SPECT BC	<b>8/4</b>	FDG-PET BC
<b>7/25</b>	SPECT TF (TBD)	<b>8/8</b>	SPECT TF (TBD)